## Company Profile SPEDLOGSWISS NORDWESTSCHWEIZ is the Northwestern Switzerland section of SpedlogSwiss, the national association for freight forwarders and logistics service providers. The section represents forwarders, customs brokers and logistics firms operating in the Basel/Argau/Schaffhausen corridor and around EuroAirport Basel (a major life‑sciences export node). Its activities focus on member networking, industry advocacy, knowledge sharing (training, best practice), and local market coordination rather than operating as a single commercial freight operator. Members handle multimodal export/import flows (air, road, rail), customs procedures and temperature‑controlled shipments for regional exporters — notably life‑sciences and industrial goods from the Basel cluster. ## Pain Points 1) Rapid rise in high‑value pharma air exports from Basel is driving urgent demand for validated cold‑chain capacity, GDP/CEIV compliance and reliable international buyer connections — small/medium forwarder members may lack the direct global network or digital tools to capture new pharma volumes. 2) Swiss customs modernisation (Passar roll‑out replacing e‑dec) creates IT and process integration burdens for forwarders and their shipper customers (new data fields, transit harmonisation with EU), increasing risk of filing errors or delays during 2025–2026 transition. 3) Capacity and coordination pressures at EuroAirport Basel (surge in pharma RKN volumes and dedicated pharma handling growth) mean members must secure slots, packaging, and contingency routing; smaller members may struggle to convert inbound business without a turnkey sourcing/sales channel. ## Intel Summary === MULTI-DIMENSION RESEARCH === === 1. COMMODITY TRENDS – SWITZERLAND PHARMACEUTICAL EXPORTS & BASEL REGION (FOCUS 2025–Q1 2026) === • **National export level & pharma share (2025–Q1 2026)** - Swiss exports reached a **record CHF 287.0 bn in 2025**, up **+1.4% YoY**. ([kmu.admin.ch](https://www.kmu.admin.ch/kmu/en/home/new/news/2026/record-exports-driven-chemicals-pharmaceuticals.html?utm_source=openai)) - **Chemicals & pharmaceuticals** reached **~CHF 152 bn in 2025**, contributing **+CHF 3.3 bn** to export growth and now account for **~53% of total Swiss exports**. ([kmu.admin.ch](https://www.kmu.admin.ch/kmu/en/home/new/news/2026/record-exports-driven-chemicals-pharmaceuticals.html?utm_source=openai)) - Industry association data (scienceindustries) confirms an **export volume of CHF 152.1 bn in 2025**, corresponding to **>52% of total exports** and stressing that the sector “defied” a difficult macro environment. ([scienceindustries.ch](https://www.scienceindustries.ch/en/article/49475/chemical-and-pharmaceutical-industries-remain-the-backbone?utm_source=openai)) - Monthly trade data show that in **March 2026**, total exports rose **1% m/m to CHF 22.4 bn**, with **chemical & pharmaceutical products up 3.6% m/m**, offsetting declines in machinery and watches. ([tradingeconomics.com](https://tradingeconomics.com/switzerland/exports?utm_source=openai)) • **Short‑term volatility in 2025** - Despite the full‑year record, **Q2 2025** saw a notable **-9.6% drop in chemical‑pharmaceutical exports**, equivalent to **–CHF 4.2 bn**, which temporarily weighed on Swiss import–export performance. ([kmu.admin.ch](https://www.kmu.admin.ch/kmu/fr/home/actuel/news/2025/import-export-souffre-recul-pharma.html?utm_source=openai)) - This underscores that while the **structural trend is strongly positive**, pharma exports are **not immune to quarterly swings** linked to patent cycles, stock adjustments and market demand. • **Basel region role and concentration of pharma** - Basel remains the **core life‑sciences hub**: around **900 pharma and medtech firms with ~50,000 employees** are located in the broader Basel region. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Life_sciences_industry_in_Switzerland?utm_source=openai)) - A 2026 regional article on “Life Sciences Hub Basel” notes that **pharmaceutical products continue to account for over 40% of Swiss exports** and that the federal customs administration reported **stable pharma exports in Q1 2026 despite a strong Swiss franc** – signaling resilience of high‑value life‑science exports, heavily concentrated in Basel companies (Roche, Novartis, Lonza and their ecosystem). ([baselpost.ch](https://baselpost.ch/life-sciences-hub-basel-2026-roche-und-novartis/?utm_source=openai)) - Interpharma (industry body) reiterates that with **CHF 105.5 bn in pharma exports (≈40.5% of total exports, earlier reference year)**, the pharma industry is Switzerland’s **most important export sector** and is under strategic scrutiny in 2026 (“pharmaceutical hub at a crossroads”). ([interpharma.ch](https://www.interpharma.ch/en/themen/starke-wirtschaftliche-rahmenbedingungen/pharmastandort-schweiz/?utm_source=openai)) • **Directional signals for 2026** - Official and industry statements in early **2026** emphasize: - Ongoing **export growth or stabilization** in pharma despite FX headwinds and geopolitical risk. ([scienceindustries.ch](https://www.scienceindustries.ch/en/article/49475/chemical-and-pharmaceutical-industries-remain-the-backbone?utm_source=openai)) - Continuing **capital and employment concentration in Basel’s life‑science cluster**, including expansions in innovation parks in Allschwil, Muttenz, Pratteln and the Switzerland Innovation Park Basel Area. ([baselpost.ch](https://baselpost.ch/life-sciences-hub-basel-2026-roche-und-novartis/?utm_source=openai)) - Risk commentary (industry and media discussions) flags **US pricing and tariff risks** for Swiss pharma exports (particularly Basel‑based majors), but these are **scenario discussions** rather than implemented measures at this point. ([reddit.com](https://www.reddit.com/r/Switzerland/comments/1nqwtyn?utm_source=openai)) **Implications for Basel‑linked pharma export flows (2026 outlook):** - **Baseline**: Pharma remains **>50% of Swiss exports by value;** trend for 2026 is **modest growth from a high base**, with **Basel continuing as the primary origin of high‑value pharma export flows**. - **Short‑term**: Expect **quarterly volatility** like Q2 2025, but **Q4 2025–Q1 2026 data show renewed momentum**, especially in chemicals/pharma sub‑segment. ([kmu.admin.ch](https://www.kmu.admin.ch/kmu/en/home/new/news/2026/record-exports-driven-chemicals-pharmaceuticals.html?utm_source=openai)) **Sources (Dimension 1):** ([kmu.admin.ch](https://www.kmu.admin.ch/kmu/en/home/new/news/2026/record-exports-driven-chemicals-pharmaceuticals.html?utm_source=openai)) === 2. DEMAND SIGNALS – BASEL AIRPORT CARGO, AIRFREIGHT & PHARMA COLD CHAIN (FOCUS 2024–2026) === • **Basel as a life‑science air cargo hub** - EuroAirport Basel–Mulhouse–Freiburg is positioned as a **key European gateway for life‑science air cargo**, serving the Basel pharma cluster (Roche, Novartis, Lonza, CDMOs and biotechs). ([swissport.com](https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai)) - A 2026 regional report indicates that **around 45% of export value shipped via airfreight from EuroAirport Basel is pharmaceutical goods**, confirming very high concentration of **value** in pharma shipments. ([baselpost.ch](https://baselpost.ch/life-sciences-hub-basel-2026-roche-und-novartis/?utm_source=openai)) • **Swissport “cool+connect” facility – concrete volume indicators** - Swissport launched its dedicated **“cool+connect” pharma facility** at Basel in **February 2025** (IATA CEIV Pharma‑certified, GDP‑compliant). ([swissport.com](https://www.swissport.com/en/content/download/136247/file/20260326_MediaRelease_SWISSPORT%20DRIVES%20PHARMA%20COLD%20CHAIN%20GROWTH%20AT%20EUROAIRPORT%20BASEL.pdf?utm_source=openai)) - As of **March 26, 2026**, Swissport reports it has handled **over 1,000 temperature‑controlled ULDs (RKN‑equivalent)** through this facility. Monthly throughput has **ramped to 200–250 RKN‑equivalents per month**, i.e. an annualized pace of roughly **2,400–3,000 active containers** if current run‑rate holds. ([swissport.com](https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai)) - The milestone is explicitly described as reflecting **“strong growth in pharmaceutical volumes”** and “increasing demand for reliable, airport‑based cold chain solutions,” reinforcing Basel’s role in **intercontinental flows to/from Asia and other key markets. ([swissport.com](https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai))** • **Capacity expansions and network context** - Swissport expanded cargo infrastructure at EuroAirport Basel in **2025**, adding **~800 m²** of additional freight space to support **pharmaceutical exports from Switzerland and imports into Europe**. The Basel warehouse is part of Swissport’s network of **24 CEIV‑certified pharma centers and 65 pharma‑capable warehouses worldwide**. ([swissport.com](https://www.swissport.com/en/news/press-release/2025/20251217_swissport_mediarelease_swissport-expands-pharmaceutical-network-to-24-certified-pharma-centers?utm_source=openai)) - Group‑wide, Swissport handled **~5 million tons of airfreight in 2024**, with **pharmaceutical shipments accounting for ~10% of that tonnage** – indicating pharma is **over‑represented in value** relative to weight, and Basel is among the flagship pharma nodes in this network. ([swissport.com](https://www.swissport.com/en/news/press-release/2025/20251217_swissport_mediarelease_swissport-expands-pharmaceutical-network-to-24-certified-pharma-centers?utm_source=openai)) • **Interpreting demand signals for 2026** - **Rising container counts (1,000+ RKN‑equivalent by March 2026 and 200–250 per month)**, plus capacity additions, are **direct, high‑frequency indicators** of **growing pharma cold‑chain demand via Basel airport**. ([swissport.com](https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai)) - The combination of: - pharma’s **>50% share of Swiss export value**, - **45% share of airfreight export value at Basel being pharma**, and - Swissport’s ongoing infrastructure investments suggests that **pharma‑linked air cargo will remain the dominant and growing segment at EuroAirport Basel in 2026**, even if total tonnage is not publicly broken out by month. ([baselpost.ch](https://baselpost.ch/life-sciences-hub-basel-2026-roche-und-novartis/?utm_source=openai)) **Sources (Dimension 2):** ([swissport.com](https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai)) === 3. MARKET EVENTS – SWISS CUSTOMS / E-DEC, PASSAR & TRANSIT RULES (2024–2026) === • **System transition: e‑dec → Passar (exports & transit)** - The **Federal Office for Customs and Border Security (FOCBS)** is replacing the legacy **e‑dec** customs declaration system with a new platform **Passar** as part of its digitalisation program. - Official guidance states that **e‑dec Export must be fully replaced by Passar by 31 December 2025**, per an agreed roadmap with the business community. ([bazg.admin.ch](https://www.bazg.admin.ch/bazg/en/home/services/services-companies/services-firmen_einfuhr-ausfuhr-durchfuhr/passar.html?utm_source=openai)) - **Passar 1.0** already covers **transit and export declarations**, implementing the **new EU transit reporting format**, which is key for EU–Switzerland transit interoperability (e.g., NCTS‑aligned data requirements). ([bazg.admin.ch](https://www.bazg.admin.ch/bazg/en/home/services/services-firmen_einfuhr-ausfuhr-durchfuhr/passar.html?utm_source=openai)) • **Import side: phased introduction of Passar 2.0 (from 2025)** - For imports, authorities plan an expansion of Passar (**Passar 2.0 for imports**) in **three phases starting 2025**, ultimately replacing **e‑dec Import** as well. ([kmu.admin.ch](https://www.kmu.admin.ch/kmu/en/home/concrete-know-how/import-export/importing-sme/customs-clearance-import.html?utm_source=openai)) - The current FOCBS SME‑oriented guidance (updated **~April 2026**) notes: - e‑dec still operates for imports/exports/transit today, - but electronic assessment decisions (DTe) via e‑dec have been **mandatory since March 2018**, and - companies should prepare for the staged migration to Passar for all traffic types. ([kmu.admin.ch](https://www.kmu.admin.ch/kmu/en/home/concrete-know-how/import-export/importing-sme/customs-clearance-import.html?utm_source=openai)) • **Implications for EU–Switzerland transit & trade in 2026** - With Passar 1.0 in place for transit, **Swiss transit declarations are increasingly harmonised with EU standards** (data structure and message formats), simplifying multimodal corridors for **EU–Switzerland–non‑EU** traffic. ([bazg.admin.ch](https://www.bazg.admin.ch/bazg/en/home/services/services-companies/services-firmen_einfuhr-ausfuhr-durchfuhr/passar.html?utm_source=openai)) - The **deadline of 31 December 2025** for replacing e‑dec Export means that **from 2026**, exporters and freight forwarders (including those moving pharma from Basel to EU airports/ports) should expect: - **Mandatory use of Passar for export and transit declarations**, - New **data field requirements** and message formats aligned with EU transit systems, - Potential **IT integration work** for customs brokers, 3PLs and large shippers connecting their ERP/TMS systems to Passar. ([bazg.admin.ch](https://www.bazg.admin.ch/bazg/en/home/services/services-companies/services-firmen_einfuhr-ausfuhr-durchfuhr/passar.html?utm_source=openai)) • **Regulatory & operational takeaways (2024–2026)** - There is **no evidence of disruptive new tariff measures or systemic tightening specifically targeting EU–Switzerland pharma trade** in the last 90 days; the focus is on **procedural and IT modernisation** rather than new duties. ([bazg.admin.ch](https://www.bazg.admin.ch/bazg/en/home/services/services-companies/services-firmen_einfuhr-ausfuhr-durchfuhr/passar.html?utm_source=openai)) - For life‑science exporters in the Basel area, the main 2024–2026 customs “events” to monitor are: - **Progress milestones in Passar roll‑out** and any transitional dual‑running with e‑dec, - Updates to **technical specifications and message formats** affecting automated customs filing, - Any **sector‑specific guidance** on handling temperature‑controlled or high‑value pharma shipments within the new system (not yet singled out in current generic FOCBS guidelines). ([kmu.admin.ch](https://www.kmu.admin.ch/kmu/en/home/concrete-know-how/import-export/importing-sme/customs-clearance-import.html?utm_source=openai)) **Sources (Dimension 3):** ([kmu.admin.ch](https://www.kmu.admin.ch/kmu/en/home/concrete-know-how/import-export/importing-sme/customs-clearance-import.html?utm_source=openai)) Sources: • Record exports driven by chemicals and pharmaceuticals https://www.kmu.admin.ch/kmu/en/home/new/news/2026/record-exports-driven-chemicals-pharmaceuticals.html?utm_source=openai • Record exports driven by chemicals and pharmaceuticals https://www.kmu.admin.ch/kmu/en/home/new/news/2026/record-exports-driven-chemicals-pharmaceuticals.html?utm_source=openai • scienceindustries - Chemical and pharmaceutical industries remain the backbone https://www.scienceindustries.ch/en/article/49475/chemical-and-pharmaceutical-industries-remain-the-backbone?utm_source=openai • Switzerland Exports https://tradingeconomics.com/switzerland/exports?utm_source=openai • L’import-export souffre du recul de la pharma https://www.kmu.admin.ch/kmu/fr/home/actuel/news/2025/import-export-souffre-recul-pharma.html?utm_source=openai • Life sciences industry in Switzerland https://en.wikipedia.org/wiki/Life_sciences_industry_in_Switzerland?utm_source=openai • Life Sciences Hub Basel 2026: Roche und Novartis https://baselpost.ch/life-sciences-hub-basel-2026-roche-und-novartis/?utm_source=openai • Switzerland as a pharma hub - Interpharma https://www.interpharma.ch/en/themen/starke-wirtschaftliche-rahmenbedingungen/pharmastandort-schweiz/?utm_source=openai • scienceindustries - Chemical and pharmaceutical industries remain the backbone https://www.scienceindustries.ch/en/article/49475/chemical-and-pharmaceutical-industries-remain-the-backbone?utm_source=openai • Life Sciences Hub Basel 2026: Roche und Novartis https://baselpost.ch/life-sciences-hub-basel-2026-roche-und-novartis/?utm_source=openai • Switzerland braces for 100% US medicine tariff https://www.reddit.com/r/Switzerland/comments/1nqwtyn?utm_source=openai • Record exports driven by chemicals and pharmaceuticals https://www.kmu.admin.ch/kmu/en/home/new/news/2026/record-exports-driven-chemicals-pharmaceuticals.html?utm_source=openai • Record exports driven by chemicals and pharmaceuticals https://www.kmu.admin.ch/kmu/en/home/new/news/2026/record-exports-driven-chemicals-pharmaceuticals.html?utm_source=openai • Swissport International AG - Swissport drives pharma cold chain growth at EuroAirport Basel https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai • Life Sciences Hub Basel 2026: Roche und Novartis https://baselpost.ch/life-sciences-hub-basel-2026-roche-und-novartis/?utm_source=openai • Basel, 26 March 2026 https://www.swissport.com/en/content/download/136247/file/20260326_MediaRelease_SWISSPORT%20DRIVES%20PHARMA%20COLD%20CHAIN%20GROWTH%20AT%20EUROAIRPORT%20BASEL.pdf?utm_source=openai • Swissport International AG - Swissport drives pharma cold chain growth at EuroAirport Basel https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai • Swissport International AG - Swissport drives pharma cold chain growth at EuroAirport Basel https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai • Zurich, 17 December 2025 https://www.swissport.com/en/news/press-release/2025/20251217_swissport_mediarelease_swissport-expands-pharmaceutical-network-to-24-certified-pharma-centers?utm_source=openai • Zurich, 17 December 2025 https://www.swissport.com/en/news/press-release/2025/20251217_swissport_mediarelease_swissport-expands-pharmaceutical-network-to-24-certified-pharma-centers?utm_source=openai • Swissport International AG - Swissport drives pharma cold chain growth at EuroAirport Basel https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai • Life Sciences Hub Basel 2026: Roche und Novartis https://baselpost.ch/life-sciences-hub-basel-2026-roche-und-novartis/?utm_source=openai • Swissport International AG - Swissport drives pharma cold chain growth at EuroAirport Basel https://www.swissport.com/en/news/current-news/2026/swissport-drives-pharma-cold-chain-growth-at-euroairport-basel?utm_source=openai • Passar https://www.bazg.admin.ch/bazg/en/home/services/services-companies/services-firmen_einfuhr-ausfuhr-durchfuhr/passar.html?utm_source=openai)